Paulson Richard A. 4
4 · Karyopharm Therapeutics Inc. · Filed Sep 16, 2025
Insider Transaction Report
Form 4
Paulson Richard A.
DirectorPresident and CEO
Transactions
- Award
Common Stock
2025-09-12+2,800→ 85,303 total - Sale
Common Stock
2025-09-15$6.43/sh−1,257$8,083→ 84,046 total
Footnotes (2)
- [F1]Represents the number of shares of the issuer's common stock underlying performance-based restricted stock units ("PSUs") granted in February 2023 that have been earned based on the level of achievement of the clinical milestone for complete enrollment in the Company's Phase 3 SENTRY trial, as certified by the issuer's Compensation Committee on September 12, 2025. Each earned PSU represents the contingent right to receive one share of the issuer's common stock upon vesting. The earned PSUs vested on September 12, 2025.
- [F2]This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of PSUs. The sale does not represent a discretionary trade by the reporting person.